13F Action: As Abbvie INC (ABBV) Valuation Rose, Stephens INC Has Upped Holding by $3.24 Million

13F Action: As Abbvie INC (ABBV) Valuation Rose, Stephens INC Has Upped Holding by $3.24 Million

Stephens Inc increased its stake in Abbvie Inc (ABBV) by 19.41% based on its latest 2016Q3 regulatory filing with the SEC. Stephens Inc bought 51,406 shares as the company’s stock rose 0.57% with the market. The institutional investor held 316,283 shares of the major pharmaceuticals company at the end of 2016Q3, valued at $19.95 million, up from 264,877 at the end of the previous reported quarter. Stephens Inc who had been investing in Abbvie Inc for a number of months, seems to be bullish on the $103.89 billion market cap company. The stock increased 1.01% or $0.64 on January 10, hitting $64.07. About 3,814 shares traded hands. AbbVie Inc (NYSE:ABBV) has risen 1.54% since June 7, 2016 and is uptrending. It has underperformed by 5.89% the S&P500.

Stephens Inc is a Arkansas-based institutional investor with more than $6.58 billion AUM in December, 2014. This fund invests only a small percentage of its assets in equities and options. Taken from Stephens latest Adv, the fund reported to have 618 full and part-time employees. Among which 294 performing investment advisory and research functions. The institutional investor had more than 7600 clients.

Insitutional Activity: The institutional sentiment increased to 1.03 in Q3 2016. Its up 0.17, from 0.86 in 2016Q2. The ratio increased, as 62 funds sold all ABBV shares owned while 559 reduced positions. 130 funds bought stakes while 512 increased positions. They now own 1.04 billion shares or 2.01% less from 1.06 billion shares in 2016Q2. North Management Corp last reported 0.12% of its portfolio in the stock. Moreover, United State Bank has 0.5% invested in AbbVie Inc (NYSE:ABBV) for 17,299 shares. Natl Bank Va accumulated 4,958 shares or 0.33% of the stock. Boston Family Office Ltd reported 94,788 shares or 0.77% of all its holdings. Cullinan Associate Inc holds 0.61% or 113,700 shares in its portfolio. Gsa Partners Ltd Liability Partnership, a United Kingdom-based fund reported 20,659 shares. Oakworth Cap holds 0.22% or 10,206 shares in its portfolio. Moreover, Bkd Wealth Advsr Limited Liability Company has 0.13% invested in AbbVie Inc (NYSE:ABBV) for 14,864 shares. Mirador Prtn Limited Partnership accumulated 0.71% or 12,745 shares. Forbes J M & Llp owns 97,048 shares or 1.67% of their US portfolio. Ironwood Inv Counsel Lc accumulated 0.54% or 18,170 shares. Nuveen Asset Mngmt Ltd Liability owns 541,713 shares or 0.2% of their US portfolio. Allsquare Wealth Management Ltd Liability reported 1,650 shares or 0.1% of all its holdings. Nichols Asset Mgmt Ltd Liability Com, a Massachusetts-based fund reported 9,780 shares. Moreover, Excalibur Management has 0.4% invested in AbbVie Inc (NYSE:ABBV) for 6,655 shares.

Insider Transactions: Since September 7, 2016, the stock had 0 buys, and 3 insider sales for $3.83 million net activity. 3,100 AbbVie Inc (NYSE:ABBV) shares with value of $192,200 were sold by HURWICH THOMAS A.. The insider CHASE WILLIAM J sold 6,600 shares worth $390,654. $3.25M worth of AbbVie Inc (NYSE:ABBV) was sold by Schumacher Laura J.

More recent AbbVie Inc (NYSE:ABBV) news were published by: Nasdaq.com which released: “AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2017” on January 10, 2017. Also Investorplace.com published the news titled: “Why AbbVie Inc (ABBV) Stock Is Still a Long-Term Winner” on December 16, 2016. Seekingalpha.com‘s news article titled: “Can Stemcentrx Change AbbVie’s Fortunes In 2017?” with publication date: January 04, 2017 was also an interesting one.

According to Zacks Investment Research, “AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie aims to help patients’ live healthier lives and collaborate on sustainable healthcare solutions.”

AbbVie Inc (NYSE:ABBV) Ratings Coverage

Out of 17 analysts covering Abbvie Inc (NYSE:ABBV), 6 rate it a “Buy”, 1 “Sell”, while 10 “Hold”. This means 35% are positive. Abbvie Inc has been the topic of 30 analyst reports since July 21, 2015 according to StockzIntelligence Inc. As per Monday, December 7, the company rating was upgraded by Jefferies. The stock has “Outperform” rating given by William Blair on Friday, February 5. The firm has “Neutral” rating by JP Morgan given on Thursday, September 8. As per Tuesday, March 15, the company rating was initiated by Deutsche Bank. The stock of AbbVie Inc (NYSE:ABBV) earned “Buy” rating by Goldman Sachs on Monday, March 7. The stock of AbbVie Inc (NYSE:ABBV) has “Overweight” rating given on Monday, November 2 by Morgan Stanley. As per Monday, June 6, the company rating was downgraded by Cowen & Co. On Tuesday, December 1 the stock rating was downgraded by Barclays Capital to “Equal-Weight”. UBS maintained the shares of ABBV in a report on Friday, October 23 with “Buy” rating. Societe Generale initiated the shares of ABBV in a report on Wednesday, April 6 with “Sell” rating.

ABBV Company Profile

AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research biopharmaceutical company. The Firm develops and markets therapies that address a range of diseases. The Firm operates in pharmaceutical products segment. The Company’s products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications in clinical development across medical specialties, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Reply

Be the First to Comment!

Notify of